{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:59:32Z","timestamp":1777478372106,"version":"3.51.4"},"reference-count":87,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cardiovascular Medicine"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.tcm.2019.11.013","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T02:36:02Z","timestamp":1575599762000},"page":"49-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Most important advances in preventive cardiology during this past decade: Viewpoint from the American Society for Preventive Cardiology"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1102-7324","authenticated-orcid":false,"given":"Nathan D.","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5810-5460","authenticated-orcid":false,"given":"Peter P.","family":"Toth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezra A.","family":"Amsterdam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10 Suppl","key":"10.1016\/j.tcm.2019.11.013_bib0001","doi-asserted-by":"crossref","first-page":"1K","DOI":"10.1016\/j.amjcard.2008.10.002","article-title":"The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia","volume":"102","author":"Fruchart","year":"2008","journal-title":"Am J Cardiol"},{"issue":"25 Pt B","key":"10.1016\/j.tcm.2019.11.013_bib0002","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.tcm.2019.11.013_bib0003","first-page":"e1046","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.tcm.2019.11.013_bib0004","first-page":"e426","volume":"138","author":"Whelton","year":"2018","journal-title":"Circulation."},{"issue":"25 Pt B","key":"10.1016\/j.tcm.2019.11.013_bib0005","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the american college of cardiology\/american heart association task force on practice guidelines","volume":"63","author":"Goff","year":"2014","journal-title":"J Am Coll Cardiol."},{"issue":"25 Pt B","key":"10.1016\/j.tcm.2019.11.013_bib0006","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1016\/j.jacc.2013.11.003","volume":"63","author":"Eckel","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"25 Pt B","key":"10.1016\/j.tcm.2019.11.013_bib0007","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1016\/j.jacc.2013.11.004","volume":"63","author":"Jensen","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2019.11.013_bib0008","unstructured":"ASCVD risk estimator plushttp:\/\/tools.acc.org\/ascvd-risk-estimator-plus\/#!\/calculate\/estimate\/accessed 10\/25\/19."},{"issue":"2","key":"10.1016\/j.tcm.2019.11.013_bib0009","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2017.10.073","article-title":"Potential U.S. population impact of the 2017 acc\/aha high blood pressure guideline","volume":"71","author":"Muntner","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.tcm.2019.11.013_bib0010","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11886-011-0229-7","article-title":"Impact of fda guidance for developing diabetes drugs on trial design: from policy to practice","volume":"14","author":"Bethel","year":"2012","journal-title":"Curr Cardiol Rep"},{"issue":"3","key":"10.1016\/j.tcm.2019.11.013_bib0011","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10741-017-9617-4","article-title":"DPP4 inhibitors and cardiovascular outcomes: safety on heart failure","volume":"22","author":"Xia","year":"2017","journal-title":"Heart Fail Rev"},{"issue":"24","key":"10.1016\/j.tcm.2019.11.013_bib0012","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1016\/j.jacc.2018.09.020","volume":"72","author":"Das","year":"2018","journal-title":"J Am Coll Cardiol."},{"issue":"22","key":"10.1016\/j.tcm.2019.11.013_bib0013","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"EMPA-REG outcome investigators. empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.tcm.2019.11.013_bib0014","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"CANVAS program collaborative group. canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.tcm.2019.11.013_bib0015","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"DECLARE-TIMI 58 investigators. dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.tcm.2019.11.013_bib0016","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"DAPA-HF trial committees and investigators. dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.tcm.2019.11.013_bib0017","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"LEADER steering committee; leader trial investigators. liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.tcm.2019.11.013_bib0018","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"SUSTAIN-6 investigators. semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.tcm.2019.11.013_bib0019","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"PIONEER 6 investigators. oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"issue":"10193","key":"10.1016\/j.tcm.2019.11.013_bib0020","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomized placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.tcm.2019.11.013_bib0021","first-page":"S103","article-title":"10. Cardiovascular disease and risk management: standards of medical care in diabetes-2019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.tcm.2019.11.013_bib0022","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.tcm.2019.11.013_bib0023","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jacl.2018.11.008","article-title":"Hypertriglyceridemia in statin-treated us adults: the national health and nutrition examination survey","volume":"13","author":"Fan","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.tcm.2019.11.013_bib0024","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jacc.2005.11.046","article-title":"Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds","volume":"47","author":"Grundy","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2019.11.013_bib0025","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1161\/01.CIR.96.3.733","article-title":"Lipoprotein lipase variants D9N and N291S are associated with increased plasma triglyceride and lower high-density lipoprotein cholesterol concentrations: studies in the fasting and postprandial states: the european atherosclerosis research studies","volume":"96","author":"Gerdes","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2019.11.013_bib0026","doi-asserted-by":"crossref","first-page":"27561","DOI":"10.1074\/jbc.M110.144279","article-title":"Angiopoietin-like protein 3 inhibits lipoprotein lipase activity through enhancing its cleavage by proprotein convertases","volume":"285","author":"Liu","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.tcm.2019.11.013_bib0027","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.tips.2018.06.001","article-title":"Novel therapeutic targets for managing dyslipidemia","volume":"39","author":"Sathiyakumar","year":"2018","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.tcm.2019.11.013_bib0028","doi-asserted-by":"crossref","first-page":"376","DOI":"10.2174\/1570161116999180613120902","article-title":"Lipoprotein subfractions in patients with acute coronary syndromes: should we reach beyond ldl-c","volume":"17","author":"Toth","year":"2019","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.tcm.2019.11.013_bib0029","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.gheart.2012.12.009","article-title":"Lipids and vascular disease: a framingham perspective","volume":"8","author":"Wilson","year":"2013","journal-title":"Glob Heart"},{"key":"10.1016\/j.tcm.2019.11.013_bib0030","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"},{"issue":"Suppl A","key":"10.1016\/j.tcm.2019.11.013_bib0031","first-page":"A2","article-title":"The munster heart study (PROCAM). results of follow-up at 8 years","volume":"19","author":"Assmann","year":"1998","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2019.11.013_bib0032","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/eurheartj\/eht571","article-title":"Mendelian randomization of blood lipids for coronary heart disease","volume":"36","author":"Holmes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2019.11.013_bib0033","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.tcm.2019.11.013_bib0034","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0140-6736(10)60659-9","article-title":"Mendelian randomisation, triglycerides, and CHD","volume":"375","author":"Pare","year":"2010","journal-title":"Lancet North Am Ed"},{"key":"10.1016\/j.tcm.2019.11.013_bib0035","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.mayocp.2019.03.028","article-title":"Association of elevated triglycerides with increased cardiovascular risk and direct costs in statin-treated patients","volume":"94","author":"Toth","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.tcm.2019.11.013_bib0036","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.008740","article-title":"High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: a real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk","volume":"7","author":"Toth","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.tcm.2019.11.013_bib0037","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the american college of cardiology\/american heart association task force on clinical practice guidelines","volume":"139","author":"Grundy Scott","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2019.11.013_bib0038","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","article-title":"Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the prove IT-TIMI 22 trial","volume":"51","author":"Miller","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2019.11.013_bib0039","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.tcm.2019.11.013_bib0040","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.jacc.2013.07.023","article-title":"Relationship of lipoproteins to cardiovascular events: the aim-high trial (Atherothrombosis intervention in metabolic syndrome with low HDL\/High triglycerides and impact on global health outcomes)","volume":"62","author":"Guyton","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2019.11.013_bib0041","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11883-009-0012-z","article-title":"Drug therapy for hypertriglyceridemia: fibrates and omega-3 fatty acids","volume":"11","author":"Toth","year":"2009","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.tcm.2019.11.013_bib0042","article-title":"Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease","volume":"11","author":"Abdelhamid","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.tcm.2019.11.013_bib0043","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamacardio.2017.5205","volume":"3","author":"Aung","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.tcm.2019.11.013_bib0044","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.plefa.2016.01.003","article-title":"Conducting omega-3 clinical trials with cardiovascular outcomes: proceedings of a workshop held at issfal 2014","volume":"107","author":"Rice","year":"2016","journal-title":"Prostagl Leukotr Essent Fatty Acids"},{"key":"10.1016\/j.tcm.2019.11.013_bib0045","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","article-title":"Effects of n\u22123 fatty acid supplements in diabetes mellitus","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2019.11.013_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2009.12.033","article-title":"Effect of low doses of n-3 fatty acids on cardiovascular diseases in 4,837 post-myocardial infarction patients: design and baseline characteristics of the alpha omega trial","volume":"159","author":"Geleijnse","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.tcm.2019.11.013_bib0047","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.tcm.2019.11.013_bib0048","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2019.11.013_bib0049","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.tcm.2019.11.013_bib0050","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2019.11.013_bib0051","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma hdl cholesterol and risk of myocardial infarction: a mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet North Am Ed"},{"key":"10.1016\/j.tcm.2019.11.013_bib0052","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2019.11.013_bib0053","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2019.11.013_bib0054","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2019.11.013_bib0055","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/clc.23055","article-title":"Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: rationale and design of the strength trial","volume":"41","author":"Nicholls","year":"2018","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.tcm.2019.11.013_bib0056","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2009.09.009","article-title":"Inflammation in atherosclerosis: from pathophysiology to practice","volume":"54","author":"Libby","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2019.11.013_bib0057","first-page":"2984","article-title":"Requiem for the 'vulnerable plaque'","volume":"36","author":"Libby","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2019.11.013_bib0058","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.jacc.2015.12.048","article-title":"Leukocytes link local and systemic inflammation in ischemic cardiovascular disease: an expanded \u201cCardiovascular continuum\u201d","volume":"67","author":"Libby","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2019.11.013_bib0059","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1161\/ATVBAHA.118.310227","article-title":"Impact of miRNA in atherosclerosis","volume":"38","author":"Lu","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.tcm.2019.11.013_bib0060","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2217\/14796678.5.1.83","article-title":"Role of nadph oxidase in atherosclerosis","volume":"5","author":"Violi","year":"2009","journal-title":"Future Cardiol"},{"key":"10.1016\/j.tcm.2019.11.013_bib0061","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1155\/2013\/659282","article-title":"Role of matrix metalloproteinase-8 in atherosclerosis","volume":"2013","author":"Lenglet","year":"2013","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.tcm.2019.11.013_bib0062","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s11883-003-0004-3","article-title":"C-reactive protein and risk of cardiovascular disease: evidence and clinical application","volume":"5","author":"Ridker","year":"2003","journal-title":"Curr Atheroscleros Rep"},{"key":"10.1016\/j.tcm.2019.11.013_bib0063","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-Reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2019.11.013_bib0064","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1161\/CIRCULATIONAHA.115.018381","article-title":"Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in improve-it","volume":"132","author":"Bohula","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2019.11.013_bib0065","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-Reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2019.11.013_bib0066","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2019.11.013_bib0067","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose metrotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2019.11.013_bib0068","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2019.11.013_bib0069","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.jacc.2011.02.005","article-title":"Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the american heart association","volume":"57","author":"Mosca L Benjamin","year":"2011","journal-title":"J Am Coll Cardio"},{"key":"10.1016\/j.tcm.2019.11.013_bib0070","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jcmg.2016.02.001","article-title":"Sex differences in demographics, risk factors, presentation, and noninvasive testing in stable outpatients with suspected coronary artery disease","volume":"9","author":"Hemal","year":"2016","journal-title":"JACC CV Imag"},{"issue":"4","key":"10.1016\/j.tcm.2019.11.013_bib0071","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1067\/mhl.2002.126105","article-title":"Symptoms of acute coronary syndromes: are there gender differences? a review of the literature","volume":"31","author":"DeVon","year":"2002","journal-title":"Heart Lung"},{"issue":"11","key":"10.1016\/j.tcm.2019.11.013_bib0072","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.amjcard.2012.07.027","article-title":"Improving the positive predictive value of exercise testing in women for coronary artery disease","volume":"110","author":"Levisman","year":"2012","journal-title":"Am J Cardiol"},{"issue":"11","key":"10.1016\/j.tcm.2019.11.013_bib0073","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1161\/CIRCULATIONAHA.111.029660","volume":"124","author":"Shaw","year":"2011","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.tcm.2019.11.013_bib0074","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.008868","article-title":"Ischemia and no obstructive coronary artery disease (INOCA): what is the risk?","author":"Herscovici","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.tcm.2019.11.013_bib0075","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.jacc.2015.05.001","article-title":"Are PCSK9 inhibitors the next breakthrough in the cardiovascular field?","volume":"65","author":"Giugliano","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2019.11.013_bib0076","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fcvm.2019.00014","article-title":"Interpreting the findings from the recent PCSK9 monoclonal antibody cardiovascular outcomes trials","volume":"6","author":"Wong","year":"2019","journal-title":"Front Cardiovasc Med"},{"issue":"22","key":"10.1016\/j.tcm.2019.11.013_bib0077","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"ODYSSEY outcomes committees and investigators. alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.tcm.2019.11.013_bib0078","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/j.jacc.2018.06.078","article-title":"Effect of evolocumab on coronary plaque composition","volume":"72","author":"Nicholls","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2019.11.013_bib0079","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jacc.2019.03.013","article-title":"Alirocumab in patients with polyvascular disease and recent acute coronary syndrome. odyssey outcomes trial","volume":"74","author":"Jukema","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2019.11.013_bib0080","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1161\/CIRCULATIONAHA.118.034309","article-title":"Clinical benefit of evolocumab by severity and extent of coronary artery disease: an analysis from fourier","volume":"138","author":"Sabatine","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2019.11.013_bib0081","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1001\/jamacardio.2018.2258","article-title":"Efficacy and safety of further lowering of low-density lipoprotein cholesterol in patients starting with very low levels. a meta-analysis","volume":"3","author":"Sabatine","year":"2018","journal-title":"JAMA Cardiol."},{"issue":"7","key":"10.1016\/j.tcm.2019.11.013_bib0082","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1701131","article-title":"EBBINGHAUS investigators. cognitive function in a randomized trial of evolocumab","volume":"377","author":"Giugliano","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2019.11.013_bib0083","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the fourier trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.tcm.2019.11.013_bib0084","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jacl.2019.05.005","article-title":"Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. a consensus statement from the national lipid association","volume":"13","author":"Robinson","year":"2019","journal-title":"J Clin Lipidol."},{"issue":"13","key":"10.1016\/j.tcm.2019.11.013_bib0085","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/CIRCULATIONAHA.118.034710","article-title":"Effect of an siRNA therapeutic targeting PCSK9 on atherogenic lipoproteins","volume":"138","author":"Ray","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2019.11.013_bib0086","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2019.3502","article-title":"Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-Year follow-up of the ORION-1 randomized clinical trial","author":"Ray","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.tcm.2019.11.013_bib0087","unstructured":"ORION-11: substantial ldl-c reduction with twice yearly dosing of novel inclisiranhttps:\/\/www.acc.org\/latest-in-cardiology\/articles\/2019\/08\/28\/13\/42\/mon-230am-orion-11-esc-2019; accessed 10\/27\/19."}],"container-title":["Trends in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105017381930163X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105017381930163X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T04:59:41Z","timestamp":1760936381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105017381930163X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S105017381930163X"],"URL":"https:\/\/doi.org\/10.1016\/j.tcm.2019.11.013","relation":{},"ISSN":["1050-1738"],"issn-type":[{"value":"1050-1738","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Most important advances in preventive cardiology during this past decade: Viewpoint from the American Society for Preventive Cardiology","name":"articletitle","label":"Article Title"},{"value":"Trends in Cardiovascular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tcm.2019.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}